![Keith D. Hall](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Keith D. Hall
Direttore operativo presso Genopis, Inc.
Posizioni attive di Keith D. Hall
Società | Posizione | Inizio | Fine |
---|---|---|---|
Genopis, Inc.
![]() Genopis, Inc. Pharmaceuticals: MajorHealth Technology Genopis, Inc. engages in the provision of biotech and pharmaceutical services. The company is headquartered in San Diego, CA. | Direttore operativo | 01/08/2018 | - |
Storia della carriera di Keith D. Hall
Precedenti posizioni note di Keith D. Hall
Società | Posizione | Inizio | Fine |
---|---|---|---|
Vical, Inc.
![]() Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Direttore operativo | 01/04/2016 | 01/08/2018 |
Corporate Officer/Principal | 01/02/2003 | 01/04/2016 | |
Agennix, Inc.
![]() Agennix, Inc. Pharmaceuticals: MajorHealth Technology Agennix, Inc. develops drugs for the treatment of cancer and wound healing. It develops liquid formulation of talactoferrin for cancer indications and a topical gel formulation for the treatment of diabetic foot ulcers. The company is headquartered in Houston, TX. | Corporate Officer/Principal | 01/01/2000 | 01/01/2003 |
Valentis, Inc.
![]() Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Corporate Officer/Principal | 01/01/1994 | 01/01/2000 |
Formazione di Keith D. Hall
University of California, Santa Barbara | Undergraduate Degree |
C. T. Bauer College of Business | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 7 |
Posizioni
Corporate Officer/Principal | 3 |
Chief Operating Officer | 2 |
Masters Business Admin | 1 |
Settori
Health Technology | 5 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 4 |
---|---|
Vical, Inc.
![]() Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
Valentis, Inc.
![]() Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Health Technology |
Agennix, Inc.
![]() Agennix, Inc. Pharmaceuticals: MajorHealth Technology Agennix, Inc. develops drugs for the treatment of cancer and wound healing. It develops liquid formulation of talactoferrin for cancer indications and a topical gel formulation for the treatment of diabetic foot ulcers. The company is headquartered in Houston, TX. | Health Technology |
Genopis, Inc.
![]() Genopis, Inc. Pharmaceuticals: MajorHealth Technology Genopis, Inc. engages in the provision of biotech and pharmaceutical services. The company is headquartered in San Diego, CA. | Health Technology |
- Borsa valori
- Insiders
- Keith D. Hall
- Esperienza